Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.

MLA

Greco, Céline, et al. “Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.” JAMA Dermatology, vol. 156, no. 2, Feb. 2020, pp. 191–95. EBSCOhost, https://doi.org/10.1001/jamadermatol.2019.4126.

APA

Greco, C., Leclerc-Mercier, S., Chaumon, S., Doz, F., Hadj-Rabia, S., Molina, T., Boucheix, C., & Bodemer, C. (2020). Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. JAMA Dermatology, 156(2), 191–195. https://doi.org/10.1001/jamadermatol.2019.4126

Chicago

Greco, Céline, Stéphanie Leclerc-Mercier, Sarah Chaumon, François Doz, Smail Hadj-Rabia, Thierry Molina, Claude Boucheix, and Christine Bodemer. 2020. “Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.” JAMA Dermatology 156 (2): 191–95. doi:10.1001/jamadermatol.2019.4126.